Since the high expression levels of BCL-2 and BCL-xL have been associated with cisplatin resistance and tumor recurrence in NSCLC patients [95], Ru31 may indirectly inhibit the resistance and relapse of lung cancer. This evidence concerns the gene BCL2 and non-small cell lung carcinoma.